{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,8,15]],"date-time":"2025-08-15T00:15:37Z","timestamp":1755216937406,"version":"3.43.0"},"reference-count":52,"publisher":"Elsevier BV","issue":"4","license":[{"start":{"date-parts":[[2025,7,1]],"date-time":"2025-07-01T00:00:00Z","timestamp":1751328000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2025,7,1]],"date-time":"2025-07-01T00:00:00Z","timestamp":1751328000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","japha.org","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Journal of the American Pharmacists Association"],"published-print":{"date-parts":[[2025,7]]},"DOI":"10.1016\/j.japh.2025.102402","type":"journal-article","created":{"date-parts":[[2025,4,15]],"date-time":"2025-04-15T15:03:53Z","timestamp":1744729433000},"page":"102402","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":0,"title":["Effects of the prescription drug monitoring program mandate on queries of controlled substance prescriptions: Findings from Texas"],"prefix":"10.1016","volume":"65","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-5775-5637","authenticated-orcid":false,"given":"Olajumoke A.","family":"Olateju","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8497-8051","authenticated-orcid":false,"given":"Mina","family":"Shrestha","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Alia","family":"Altaie","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Tyler J.","family":"Varisco","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6017-7500","authenticated-orcid":false,"given":"J. Douglas","family":"Thornton","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"author":"Becker","key":"10.1016\/j.japh.2025.102402_bib1"},{"issue":"3","key":"10.1016\/j.japh.2025.102402_bib3","doi-asserted-by":"crossref","first-page":"437","DOI":"10.3390\/healthcare11030437","article-title":"Evaluating state-level prescription drug monitoring program (PDMP) and pill mill effects on opioid consumption in pharmaceutical supply chain","volume":"11","author":"Sahebi-Fakhrabad","year":"2023","journal-title":"Healthcare"},{"issue":"10","key":"10.1016\/j.japh.2025.102402_bib4","doi-asserted-by":"crossref","first-page":"1784","DOI":"10.1111\/add.13860","article-title":"Impact of prescription drug monitoring programs (PDMPs) on opioid utilization among Medicare beneficiaries in 10 US States","volume":"112","author":"Moyo","year":"2017","journal-title":"Addiction"},{"issue":"3","key":"10.1016\/j.japh.2025.102402_bib6","doi-asserted-by":"crossref","first-page":"461","DOI":"10.1377\/hlthaff.2020.01316","article-title":"Provider compliance with Kentucky's prescription drug monitoring program's mandate to query patient opioid history","volume":"40","author":"Carey","year":"2021","journal-title":"Health Aff"},{"issue":"8","key":"10.1016\/j.japh.2025.102402_bib9","doi-asserted-by":"crossref","first-page":"1191","DOI":"10.2105\/AJPH.2020.305696","article-title":"A history of prescription drug monitoring programs in the United States: political appeal and public health efficacy","volume":"110","author":"Holmgren","year":"2020","journal-title":"Am J Public Health"},{"author":"Davis","key":"10.1016\/j.japh.2025.102402_bib11"},{"issue":"6","key":"10.1016\/j.japh.2025.102402_bib13","doi-asserted-by":"crossref","first-page":"e14","DOI":"10.1016\/j.japh.2021.06.019","article-title":"Pharmacists should treat patients who have opioid use disorders, not police them","volume":"61","author":"Chiarello","year":"2021","journal-title":"J Am Pharm Assoc"},{"year":"2021","series-title":"Dosing Discrimination: Regulating PDMP risk Scores","author":"Oliva","key":"10.1016\/j.japh.2025.102402_bib14"},{"issue":"1","key":"10.1016\/j.japh.2025.102402_bib15","doi-asserted-by":"crossref","first-page":"77","DOI":"10.1257\/pol.20160094","article-title":"The effect of prescription drug monitoring programs on opioid utilization in Medicare","volume":"10","author":"Buchmueller","year":"2018","journal-title":"Am Econ J Econ Policy"},{"issue":"10","key":"10.1016\/j.japh.2025.102402_bib16","doi-asserted-by":"crossref","first-page":"1773","DOI":"10.1111\/add.13741","article-title":"Do more robust prescription drug monitoring programs reduce prescription opioid overdose?","volume":"112","author":"Pardo","year":"2017","journal-title":"Addiction"},{"issue":"3","key":"10.1016\/j.japh.2025.102402_bib17","doi-asserted-by":"crossref","first-page":"1","DOI":"10.15585\/mmwr.rr7103a1","article-title":"CDC clinical practice guideline for prescribing opioids for pain \u2014 United States, 2022","volume":"71","author":"Dowell","year":"2023","journal-title":"MMWR Recomm Rep"},{"issue":"6","key":"10.1016\/j.japh.2025.102402_bib18","doi-asserted-by":"crossref","first-page":"754","DOI":"10.1016\/j.sapharm.2018.09.007","article-title":"Utilization of prescription drug monitoring programs for prescribing and dispensing decisions: results from a multi-site qualitative study","volume":"15","author":"Freeman","year":"2019","journal-title":"Res Soc Adm Pharm"},{"issue":"1","key":"10.1016\/j.japh.2025.102402_bib19","doi-asserted-by":"crossref","first-page":"181","DOI":"10.1002\/pam.22098","article-title":"Mandatory access prescription drug monitoring programs and prescription drug abuse","volume":"38","author":"Grecu","year":"2019","journal-title":"J Policy Anal Manag"},{"issue":"1","key":"10.1016\/j.japh.2025.102402_bib20","doi-asserted-by":"crossref","first-page":"1326","DOI":"10.1186\/s12889-023-16256-9","article-title":"Prescription drug monitoring programs use mandates and prescription stimulant and depressant quantities","volume":"23","author":"Gunadi","year":"2023","journal-title":"BMC Public Health"},{"issue":"8","key":"10.1016\/j.japh.2025.102402_bib21","doi-asserted-by":"crossref","first-page":"767","DOI":"10.1001\/jamapsychiatry.2018.0611","article-title":"Making the opioid public health emergency effective","volume":"75","author":"Haffajee","year":"2018","journal-title":"JAMA Psychiatry"},{"issue":"3","key":"10.1016\/j.japh.2025.102402_bib22","first-page":"299","article-title":"Mandatory review of prescription drug monitoring program before issuance of a controlled substance results in overall reduction of prescriptions including opioids and benzodiazepines","volume":"23","author":"Manders","year":"2020","journal-title":"Pain Physician"},{"issue":"3","key":"10.1016\/j.japh.2025.102402_bib23","doi-asserted-by":"crossref","first-page":"265","DOI":"10.1007\/s13181-021-00837-4","article-title":"Impact of a mandatory prescription drug monitoring program check on emergency department opioid prescribing rates","volume":"17","author":"Watson","year":"2021","journal-title":"J Med Toxicol"},{"issue":"9","key":"10.1016\/j.japh.2025.102402_bib24","doi-asserted-by":"crossref","first-page":"1550","DOI":"10.1377\/hlthaff.2019.00103","article-title":"Prescription drug monitoring program mandates: impact on opioid prescribing and related hospital use","volume":"38","author":"Wen","year":"2019","journal-title":"Health Aff"},{"issue":"4","key":"10.1016\/j.japh.2025.102402_bib25","doi-asserted-by":"crossref","first-page":"733","DOI":"10.1377\/hlthaff.2016.1141","article-title":"States with prescription drug monitoring mandates saw a reduction in opioids prescribed to medicaid enrollees","volume":"36","author":"Wen","year":"2017","journal-title":"Health Aff"},{"issue":"7","key":"10.1016\/j.japh.2025.102402_bib26","doi-asserted-by":"crossref","first-page":"610","DOI":"10.1097\/MLR.0000000000001322","article-title":"State policies for prescription drug monitoring programs and adverse opioid-related hospital events","volume":"58","author":"Wen","year":"2020","journal-title":"Med Care"},{"issue":"1","key":"10.1016\/j.japh.2025.102402_bib27","doi-asserted-by":"crossref","first-page":"44","DOI":"10.1056\/NEJMsa1514387","article-title":"State legal restrictions and prescription-opioid use among disabled adults","volume":"375","author":"Meara","year":"2016","journal-title":"N Engl J Med"},{"issue":"2","key":"10.1016\/j.japh.2025.102402_bib28","doi-asserted-by":"crossref","first-page":"139","DOI":"10.1177\/003335491412900207","article-title":"Prescription drug monitoring and dispensing of prescription opioids","volume":"129","author":"Brady","year":"2014","journal-title":"Public Health Rep"},{"key":"10.1016\/j.japh.2025.102402_bib29","doi-asserted-by":"crossref","DOI":"10.1136\/bmj.g1393","article-title":"Opioid prescribing by multiple providers in Medicare: retrospective observational study of insurance claims","volume":"348","author":"Jena","year":"2014","journal-title":"BMJ"},{"issue":"6","key":"10.1016\/j.japh.2025.102402_bib30","doi-asserted-by":"crossref","first-page":"964","DOI":"10.1377\/hlthaff.2017.1321","article-title":"Four states with robust prescription drug monitoring programs reduced opioid dosages","volume":"37","author":"Haffajee","year":"2018","journal-title":"Health Aff"},{"issue":"4","key":"10.1016\/j.japh.2025.102402_bib31","doi-asserted-by":"crossref","first-page":"492","DOI":"10.1002\/pds.5198","article-title":"Factors associated with the use of the prescription monitoring program by prescribers and pharmacists in Texas","volume":"30","author":"Thornton","year":"2021","journal-title":"Pharmacoepidemiol Drug Saf"},{"author":"Price","key":"10.1016\/j.japh.2025.102402_bib32"},{"issue":"6","key":"10.1016\/j.japh.2025.102402_bib33","doi-asserted-by":"crossref","first-page":"577","DOI":"10.1001\/jamasurg.2021.0528","article-title":"STROBE reporting guidelines for observational studies","volume":"156","author":"Ghaferi","year":"2021","journal-title":"JAMA Surg"},{"issue":"3","key":"10.1016\/j.japh.2025.102402_bib34","doi-asserted-by":"crossref","first-page":"1106","DOI":"10.1111\/ajps.12818","article-title":"Placebo tests for causal inference","volume":"68","author":"Eggers","year":"2024","journal-title":"Am J Polit Sci"},{"author":"Warton","key":"10.1016\/j.japh.2025.102402_bib36"},{"issue":"1","key":"10.1016\/j.japh.2025.102402_bib37","doi-asserted-by":"crossref","first-page":"137","DOI":"10.1186\/s12874-019-0777-x","article-title":"Methodology and reporting characteristics of studies using interrupted time series design in healthcare","volume":"19","author":"Hudson","year":"2019","journal-title":"BMC Med Res Methodol"},{"issue":"1","key":"10.1016\/j.japh.2025.102402_bib38","first-page":"348","article-title":"Interrupted time series regression for the evaluation of public health interventions: a tutorial","volume":"46","author":"Bernal","year":"2017","journal-title":"Int J Epidemiol"},{"key":"10.1016\/j.japh.2025.102402_bib39","series-title":"StatPearls","article-title":"Prescription drug monitoring program","author":"D'Souza","year":"2025"},{"issue":"11-12","key":"10.1016\/j.japh.2025.102402_bib40","first-page":"28","article-title":"Prescription monitoring programs: to use or not to use","volume":"10","author":"Heagerty","year":"2013","journal-title":"Innov Clin Neurosci"},{"issue":"3","key":"10.1016\/j.japh.2025.102402_bib41","first-page":"29","article-title":"The PMP requirement begins","volume":"116","author":"Berlin","year":"2020","journal-title":"Tex Med"},{"author":"Kates","key":"10.1016\/j.japh.2025.102402_bib42"},{"issue":"35","key":"10.1016\/j.japh.2025.102402_bib43","doi-asserted-by":"crossref","first-page":"1198","DOI":"10.15585\/mmwr.mm6935a2","article-title":"Timing of state and Territorial COVID-19 stay-at-home orders and changes in population movement - United States, March 1-may 31, 2020","volume":"69","author":"Moreland","year":"2020","journal-title":"MMWR Morb Mortal Wkly Rep"},{"issue":"2","key":"10.1016\/j.japh.2025.102402_bib49","doi-asserted-by":"crossref","DOI":"10.2196\/25835","article-title":"Use of telehealth in substance Use disorder services during and after COVID-19: online survey study","volume":"8","author":"Molfenter","year":"2021","journal-title":"JMIR Ment Health"},{"author":"Benton","key":"10.1016\/j.japh.2025.102402_bib50"},{"issue":"6","key":"10.1016\/j.japh.2025.102402_bib51","article-title":"Prescription drug monitoring program use by opioid prescribers: a cross-sectional study","volume":"1","author":"Sacarny","year":"2023","journal-title":"Health Aff Sch"},{"issue":"2","key":"10.1016\/j.japh.2025.102402_bib52","doi-asserted-by":"crossref","first-page":"421","DOI":"10.1007\/s11096-022-01523-3","article-title":"Factors associated with prescription drug monitoring program utilisation: a cross-sectional survey of community pharmacists","volume":"45","author":"Picco","year":"2023","journal-title":"Int J Clin Pharm"},{"issue":"1","key":"10.1016\/j.japh.2025.102402_bib53","doi-asserted-by":"crossref","first-page":"178","DOI":"10.1016\/j.japh.2019.06.016","article-title":"Pharmacist roles, training, and perceived barriers in naloxone dispensing: a systematic review","volume":"60","author":"Thakur","year":"2020","journal-title":"J Am Pharm Assoc"},{"issue":"9","key":"10.1016\/j.japh.2025.102402_bib54","doi-asserted-by":"crossref","first-page":"2026","DOI":"10.1002\/hec.4360","article-title":"The complementarity of drug monitoring programs and health IT for reducing opioid-related mortality and morbidity","volume":"30","author":"Wang","year":"2021","journal-title":"Health Econ"},{"key":"10.1016\/j.japh.2025.102402_bib57","doi-asserted-by":"crossref","first-page":"169","DOI":"10.1016\/j.drugalcdep.2018.03.036","article-title":"Mandatory review of a prescription drug monitoring program and impact on opioid and benzodiazepine dispensing","volume":"188","author":"Winstanley","year":"2018","journal-title":"Drug Alcohol Depend"},{"key":"10.1016\/j.japh.2025.102402_bib58","doi-asserted-by":"crossref","DOI":"10.1016\/j.drugalcdep.2020.108460","article-title":"Barriers and facilitators to PDMP IS Success in the US: a systematic review","volume":"219","author":"Martin","year":"2021","journal-title":"Drug Alcohol Depend"},{"issue":"7","key":"10.1016\/j.japh.2025.102402_bib59","doi-asserted-by":"crossref","first-page":"1570","DOI":"10.1093\/pm\/pnaa412","article-title":"Health care provider utilization of prescription monitoring programs: a systematic review and meta-analysis","volume":"22","author":"Robinson","year":"2021","journal-title":"Pain Med"},{"issue":"4","key":"10.1016\/j.japh.2025.102402_bib60","doi-asserted-by":"crossref","first-page":"455","DOI":"10.1177\/1090198111418108","article-title":"The extended parallel process model: illuminating the gaps in research","volume":"39","author":"Popova","year":"2012","journal-title":"Health Educ Behav"},{"issue":"5","key":"10.1016\/j.japh.2025.102402_bib61","doi-asserted-by":"crossref","first-page":"568","DOI":"10.1016\/j.japh.2018.06.003","article-title":"Pharmacists' attitudes, knowledge, utilization, and outcomes involving prescription drug monitoring programs: a brief scoping review","volume":"58","author":"Johnston","year":"2018","journal-title":"J Am Pharm Assoc"},{"issue":"5","key":"10.1016\/j.japh.2025.102402_bib62","doi-asserted-by":"crossref","first-page":"614","DOI":"10.1016\/j.japh.2021.04.019","article-title":"Predictors of pharmacists' likelihood to query prescription drug monitoring program databases","volume":"61","author":"Arnold","year":"2021","journal-title":"J Am Pharm Assoc"},{"issue":"5","key":"10.1016\/j.japh.2025.102402_bib63","doi-asserted-by":"crossref","first-page":"e91","DOI":"10.1016\/j.amepre.2018.02.009","article-title":"Psychosocial correlates of clinicians' prescription drug monitoring program utilization","volume":"54","author":"Pugliese","year":"2018","journal-title":"Am J Prev Med"},{"issue":"3","key":"10.1016\/j.japh.2025.102402_bib64","first-page":"212","article-title":"Pharmacist-led interventions to reduce drug-related problems in prescribing for pediatric outpatients in a developing Country: a randomized controlled trial","volume":"28","author":"Nguyen","year":"2023","journal-title":"J Pediatr Pharmacol Ther"},{"key":"10.1016\/j.japh.2025.102402_bib65","doi-asserted-by":"crossref","DOI":"10.1016\/j.jsat.2021.108440","article-title":"Impact of a pharmacist-led substance use disorder transitions of care clinic on postdischarge medication treatment retention","volume":"130","author":"Smith","year":"2021","journal-title":"J Subst Abuse Treat"},{"key":"10.1016\/j.japh.2025.102402_bib66","doi-asserted-by":"crossref","first-page":"127","DOI":"10.2147\/SAR.S351096","article-title":"The role of the pharmacist in combating the opioid crisis: an Update","volume":"13","author":"Kosobuski","year":"2022","journal-title":"Subst Abuse Rehabil"}],"container-title":["Journal of the American Pharmacists Association"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1544319125000810?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1544319125000810?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,8,4]],"date-time":"2025-08-04T23:13:34Z","timestamp":1754349214000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1544319125000810"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,7]]},"references-count":52,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2025,7]]}},"alternative-id":["S1544319125000810"],"URL":"https:\/\/doi.org\/10.1016\/j.japh.2025.102402","relation":{},"ISSN":["1544-3191"],"issn-type":[{"type":"print","value":"1544-3191"}],"subject":[],"published":{"date-parts":[[2025,7]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Effects of the prescription drug monitoring program mandate on queries of controlled substance prescriptions: Findings from Texas","name":"articletitle","label":"Article Title"},{"value":"Journal of the American Pharmacists Association","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.japh.2025.102402","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 American Pharmacists Association\u00ae. Published by Elsevier Inc. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}],"article-number":"102402"}}